Joëlle Guilhot

5PUBLICATIONS

11CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursNuclear and plasma physics not elsewhere classified

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|Nov 01, 2024

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.

François Guilhot, Rüdiger Hehlmann

|Jan 23, 2021

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Francois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot

|Feb 12, 2020

Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.

Tom Hähnel, Christoph Baldow, Joëlle Guilhot

|Apr 06, 2019

Ponatinib and platelets a conflict in CML.

François Guilhot

Pageof 1

Frequent Collaborators

2 joint publications

Tom Hähnel

2 joint publications

Christoph Baldow

2 joint publications

Stephanie Dulucq

2 joint publications

Ingmar Glauche

1 joint publications

Alain Delmer

1 joint publications

Emmanuel Gyan

1 joint publications

Bertrand Joly

1 joint publications

Eric Deconinck

1 joint publications

Jean-Claude Chomel

1 joint publications

Ludovic Lhermitte

Frequent Collaborators

2 joint publications

Tom Hähnel

2 joint publications

Christoph Baldow

2 joint publications

Stephanie Dulucq

2 joint publications

Ingmar Glauche